哮喘联盟

   摘要
   本综述回顾分析了24项奥马珠单抗治疗重度过敏性哮喘的“真实生活”有效性研究，包含了32个国家的4,117例患者，其中患者、医生及就诊地点均有显著差异。结果进一步凸显了抗IgE治疗的短期和长期获益，具体如下：改善肺功能；实现哮喘控制，改善症状，减少重度急性发作及相关的误工/误学；减少医疗资源使用，尤其是住院次数、住院时间、计划外访视，急诊就诊；减少或停用其他哮喘药物；以及改善生活质量。以上发现证实了随机试验的证据，是随机试验证据的有力补充，并使证据得到进一步扩展。因此，奥马珠单抗的应用与重度过敏性哮喘客观性和主观性疾病负担的显著改善有关。奥马珠单抗的获益可达2-4年，大部分使用奥马珠单抗的患者可持续多年获益。奥马珠单抗具有较好的短期和长期安全性，与已知的随机临床试验结果类似。初始使用奥马珠单抗的患者，需要连续监测16周以观察治疗反应。治疗反应明确的患者更易获得持久的治疗效果、较好的临床转归、生活质量的改善，以及医疗资源使用的减少。
 

（杨冬 审校）
Allergy. 2015 Dec 8.doi: 10.1111/all.12815. [Epub ahead of print]

 

"Real-life" effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review.
 

Abraham I1,2,3, Alhossan A1,4, Lee CS5, Kutbi H1,6, MacDonald K3.
 

Abstract
We reviewed 24 'real-life' effectiveness studies of omalizumab in the treatment of severe allergic asthma that included 4117 unique patients from 32 countries with significant heterogeneity in patients, clinicians, and settings. The evidence underscores the short- and long-term benefit of anti-IgE therapy in terms of: improving lung function; achieving asthma control and reducing symptomatology, severe exacerbations, and associated work/school days lost; reducing healthcare resource utilizations, in particular hospitalizations, hospital lengths-of-stay, and accident specialist or emergency department visits; and reducing or discontinuing other asthma medications; and improving quality of life - thus confirming, complementing, and extending evidence from randomized trials. Thus omalizumab therapy is associated with signal improvements across the full objective and subjective burden of illness chain of severe allergic asthma. Benefits of omalizumab may extend up to 2 to 4 years and the majority of omalizumab-treated patients may benefit for many years. Omalizumab has positive short- and long-term safety profiles similar to what is known from randomized clinical trials. Initiated patients should be monitored for treatment response at 16 weeks. Those showing positive response at that time are highly likely to show sustained treatment response and benefit in terms of clinical, quality of life, and health resource utilization outcomes.
 

Allergy. 2015 Dec 8.doi: 10.1111/all.12815. [Epub ahead of print]